224 related articles for article (PubMed ID: 18831523)
1. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
Malesci A; Angelucci E; Bonifacio C; Sociale O; Omodei P; Repici A; Balzarini L; Danese S
Inflamm Bowel Dis; 2009 Jun; 15(6):814-5. PubMed ID: 18831523
[No Abstract] [Full Text] [Related]
2. Onset of severe perianal disease in Crohn's disease under treatment with infliximab: successful treatment with adalimumab and setons drainage.
Tursi A; Papa A; Maiorano M
Inflamm Bowel Dis; 2011 Feb; 17(2):676-8. PubMed ID: 20848475
[No Abstract] [Full Text] [Related]
3. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
4. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
[TBL] [Abstract][Full Text] [Related]
5. [The use of adalimumab in severe fistulising Crohn's disease].
Bang UC; Nielsen AM
Ugeskr Laeger; 2008 Jun; 170(25):2256. PubMed ID: 18565318
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice.
Bourikas LA; Koutroubakis IE
Curr Drug Targets; 2010 Feb; 11(2):187-97. PubMed ID: 19916954
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab for cutaneous metastatic Crohn's disease.
Cury DB; Moss AC; Elias G; Nakao A
Inflamm Bowel Dis; 2010 May; 16(5):723-4. PubMed ID: 19728388
[No Abstract] [Full Text] [Related]
8. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
9. How deep is remission in perianal Crohn's disease and do imaging modalities matter?
Savoye G; Savoye-Collet C
Am J Gastroenterol; 2010 Jun; 105(6):1445-6; author reply 1446. PubMed ID: 20523317
[No Abstract] [Full Text] [Related]
10. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
Jürgens M; Brand S; Filik L; Hübener C; Hasbargen U; Beigel F; Tillack C; Göke B; Ochsenkühn T; Seiderer J
Inflamm Bowel Dis; 2010 Oct; 16(10):1634-6. PubMed ID: 20027647
[No Abstract] [Full Text] [Related]
11. CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapy.
Maggi L; Capone M; Giudici F; Santarlasci V; Querci V; Liotta F; Ficari F; Maggi E; Tonelli F; Annunziato F; Cosmi L
Int Arch Allergy Immunol; 2013; 161(1):81-6. PubMed ID: 23257766
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab for perianal fistulizing Crohn's disease: real-world data adds important information for clinical practice.
Kotze PG; Spinelli A
J Clin Gastroenterol; 2015 Feb; 49(2):174-5. PubMed ID: 25159683
[No Abstract] [Full Text] [Related]
13. [Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study].
López Palacios N; Mendoza JL; Taxonera C; Lana R; Fuentes Ferrer M; Díaz-Rubio M
Rev Esp Enferm Dig; 2008 Nov; 100(11):676-81. PubMed ID: 19159170
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
15. [Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?].
Bode M; Eder S; Schürmann G
Z Gastroenterol; 2008 Dec; 46(12):1376-83. PubMed ID: 19053007
[TBL] [Abstract][Full Text] [Related]
16. Local injection of adalimumab for perianal Crohn's disease: better than infliximab?
Poggioli G; Laureti S; Pierangeli F; Bazzi P; Coscia M; Gentilini L; Gionchetti P; Rizzello F
Inflamm Bowel Dis; 2010 Oct; 16(10):1631. PubMed ID: 20848458
[No Abstract] [Full Text] [Related]
17. Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
Castaño-Milla C; Chaparro M; Saro C; Barreiro-de Acosta M; García-Albert AM; Bujanda L; Martín-Arranz MD; Carpio D; Muñoz F; Manceñido N; García-Planella E; Piqueras M; Calvet X; Cabriada JL; Botella B; Bermejo F; Gisbert JP
J Clin Gastroenterol; 2015 Jan; 49(1):34-40. PubMed ID: 25485513
[TBL] [Abstract][Full Text] [Related]
18. [Adalimumab therapy in Crohn's disdease].
Baryshnikov EN; Lazebnik LB; Parfenov AI
Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
20. Esophageal Crohn's disease treated successfully with adalimumab.
Kwan LY; Conklin JL; Papadakis KA
Inflamm Bowel Dis; 2007 May; 13(5):639-40. PubMed ID: 17221856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
